EUROPEAN MULTIDISCIPLINARY ON UROLOGICAL CANCERS..

9th European Multidisciplinary Meeting on Urological Cancers

 

16-19 November 2017 Barcelona
Close
N. Poster
Poster title
Applicant name
Status
  P-001 The role of PCA3 urine test in prostatic cancer diagnosis at repeat biopsy Basheer Elmohamady Saad Received Received
  P-008 Diagnostic value of combining ipsilateral random with MRI targeted biopsies: A case series Ather abdelbaky Received Received
  P-009 PI-RADS as a tool for estimating prostate cancer stage and extension of resection Mieszko Kozikowski Received Received
  P-013 Age. An exponential risk factor for prostate cancer GUILLERMO BARBAS Received Received
  P-017 PSA screening: Does shared decision making permit doctor-patient communication? James Talcott Received Received
  P-019 A Pilot study to evaluate Next Generation DNA Sequencing Testing in rectal swabs prior to transrectal prostate biopsy Vladimir Mouraviev Received Received
  P-024 MRI-guided focal salvage high-dose-rate brachytherapy for locally recurrent prostate cancer Marieke van Son Received Received
  P-027 Comparative effectiveness of survival among surgery and radiotherapy for clinical localized prostate cancer Masato Yasui Received Received
  P-028 Single 19Gy fraction high dose rate brachytherapy for intermediate risk prostate cancer: feasibility and acute toxicity Alberto BOSSI Received Received
  P-031 Brachytherapy preserving sexual function in prostate cancer patients: The role of hyaluronic acid injection. Marina Arangena Peñacoba Received Received
  P-035 Incidental Prostate Cancer (Stage T1a-T1b): Therapeutic Options Mário José Pereira Loureno Received Received
  P-038 10-year Mortality in Men With Non-metastatic Prostate Cancer in Norway Kirsti Aas Received Received
  P-048 The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) Kristy Maguire Received Received
  P-053 Triptorelin and lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicentre, non-interventional, prospective study Ma Wenyue Received Received
  P-054 177 Lutetium PSMA -617 in metastatic castration resistant prostate cancer: Initial clinical experience HEINZ NICOLAI Received Received
  P-055 Emerging therapy treatment patterns among Danish metastatic castrate-resistant prostate cancer patients ANOUCHKA SEESAGHUR Received Received
  P-056 Efficacy and safety of abiraterone acetate and enzalutamide treatment in a real-world setting in elderly chemotherapy-nave patients ( 75 years old) Beatriz Anton Received Received
  P-058 Oligometastatic prostate cancer patients treated with curative radiotherapy FABIANA BELLAFIORE Received Received
  P-064 Clinical pathway improves implementation of evidence-based strategies for the management of androgen deprivation therapyinduced side effects in prostate cancer patients Bultijnck Renée Received Received
  P-068 Diffusion-weighted magnetic resonance imaging provides a useful biomarker for evaluation radiotherapy efficacy in patients with prostate cancer Xingchen Wu Received Received
  P-070 Prostate cancer outcomes Norway (PCO-Norway): A national, prospective collection of patient reported outcome measures (PROMs) Ylva Maria Gjelsvik Received Received
  P-074 Salvage pelvic radiotherapy for recurrent prostate cancer Eric Ka Chai Lee Received Received
  P-080 Effect of gonadotrophin-releasing hormone antagonist induced follicle-stimulating hormone suppression on prostate-specific antigen response Bo-Eric Persson Received Received
  P-083 Dose-escalated salvage radiotherapy in prostate cancer Piet Dirix Received Received
  P-087 Overexpression of periostin in tumor biopsies is associated with aggressive prostate cancer phenotype and poor clinical outcome Carlo Cattrini Received Received
  P-095 Involvement of contralateral kidney in development of acute kidney injury in laparoscopic partial nephrectomy for elective indications Sergey Dimitriadi Received Received
  P-096 Renal protective effect of procaine blocking in a model of unilateral renal ischemia-reperfusion in experiment Sergey Dimitriadi Received Received
  P-097 Organ-preserving surgery for localized renal cell carcinoma: A modern approach Sergey Dimitriadi Received Received
  P-098 90 days postoperative outcomes of nephron-sparing surgery for solitary kidney tumors Denis Ledyaev Received Received
  P-101 Efficacy of incomplete metastasectomy with targeted therapy in patients with metastatic renal cell carcinoma Pavel Borisov Received Received
  P-107 Quality of life in patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapies Beatriz Anton Received Received
  P-113 Long term overall survival (OS) in patients with primary metastatic kidney cancer: an analysis of 1468 patients from the Austrian National Cancer Registry (ANCR). Martin Marszalek Received Received
  P-116 Survival prediction in axitinib-treated patients with metastatic renal cell carcinoma RYUICHI MIZUNO Received Received
  P-122 Targeted high-throughput sequencing identifies mutations associated with clear cell-renal carcinoma: A population-based study Krzysztof Ratajczyk Received Received
  P-131 Diagnostic and treatment approach of urachal adenocarcinoma. Report of 3 cases and review of literature Juan Daniel Martinez Ledesma Received Received
  P-132 Interferon alfa2b induction usefulness in non-muscle-invasive bladder cancer compared to BCG Eduardo Albers Received Received
  P-138 Phase 1b trial of cabozantinib in combination with atezolizumab in patientswith locally advanced or metastatic urothelial carcinoma or renal cell carcinoma Cara Ziegenbein Received Received
  P-145 A multicenter, randomized phase II trial of vinflunine/gemcitabine versus carboplatin/gemcitabine as first line treatment in patients with metastatic urothelial carcinoma unfit for cisplatin based chemotherapy due to impaired renal functionVINGEM Karin Holmsten Received Received
  P-148 Prognostic models for nonmetastatic urothelial tract urinary cancer (utuc) after curative treatment in a mediterranean caucasian population MARIA ISABEL RODRIGUEZ CRUZ Received Received
  P-152 Signet ring cell component combined with Mayo Clinic staging system in urachal carcinoma: A more accurate prognostic factor Susumu Umemoto Received Received
  P-153 Expression of MICA and NKG2D predicts recurrence and progression of primary non-muscle invasive bladder cancer Enrique Rijo Received Received
  P-155 The over time conditional survival and evaluation of intravesical recurrence in upper tract urothelial carcinoma Keisuke Shigeta Received Received
  P-158 Purified protein derivative skin test reactions are associated with tumor recurrence rate in patients with non-muscle invasive bladder cancer treated with bacillus-Calmette Guérin Keisuke Shigeta Received Received
  P-166 Do small leydig cell tumours require follow up? Bingyuan Yang Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:30, Fri 8:30-15:00
18:06
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

EUROPEAN MULTIDISCIPLINARY ON UROLOGICAL CANCERS..

9th European Multidisciplinary Meeting on Urological Cancers

 

16-19 November 2017 Barcelona
HELP LINE
Manage Orders
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 16/11/2017 TO 16/11/2017
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.EMUC2017.2017 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 07/11/2017
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster




PosterSessionOnline
Logo Draft
 
Logo Cert